drugset / Trial / NCT04545008
Trial of Famotidine & N-Acetyl Cysteine for Outpatients With COVID-19
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this trial is to assess the safety and toxicity profile of the combination of famotidine and oral n-acetyl cysteine in adult outpatients with newly diagnosed SARS-CoV-2 infection.
Timeline
- Start
- 2020-10-20
- Primary completion
- 2021-06-02
- Completion
- 2021-06-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Famotidine | Other / unclassified | 20 mg | Oral |
| Subject | Famotidine | Other / unclassified | 40 mg | Oral |
| Subject | Famotidine | Other / unclassified | 80 mg | Oral |
| Subject | N-acetylcysteine | Small molecule | 600 mg | Oral |
| Subject | N-acetylcysteine | Small molecule | 1200 mg | Oral |
| Subject | N-acetylcysteine | Small molecule | 1800 mg | Oral |